Esperion to acquire Corstasis for $75M upfront; adds Enbumyst nasal spray for heart failure edema

Esperion Therapeutics, Inc.

Esperion acquires Corstasis for $75M cash upfront; up to $180M in milestones plus low double-digit royalties on Enbumyst sales.
Enbumyst (bumetanide nasal spray) is first FDA-approved nasal spray diuretic for edema in CHF, hepatic, renal disease (approved Sep 2025).
Esperion expects to leverage its cardiovascular commercial infrastructure to drive double-digit revenue growth; addresses $4B+ U.S. market.
Transaction financed via existing credit facilities and royalty monetization; expected close Q2 2026.
Corstasis also developing subcutaneous multidose pen injector; complements Esperion's pipeline in metabolic, hepatic, renal disease.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Esperion Therapeutics, Inc. entered into Agreement and Plan of Merger with Corstasis Therapeutics Inc., a Delaware corporation (“Corstasis”), and Cirrus Transaction Subsidiary, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”) valued at $75,000,000 (effective 2026-03-02).

Action: entry
Agreement: merger
Counterparty: Corstasis Therapeutics Inc., a Delaware corporation (“Corstasis”), and Cirrus Transaction Subsidiary, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”)
Value: $75,000,000
Effective: 2026-03-02

Exact text from the filing

On March 2, 2026, Esperion Therapeutics, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Corstasis Therapeutics Inc., a Delaware corporation (“Corstasis”), and Cirrus Transaction Subsidiary, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”).

View on SEC.gov

291 material agreements filed in the last 30 days. Browse all material agreements →

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-013552

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.